Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia - Changes in serum potassium levels with or without a RAAS inhibitor

Clinical Nephrology

Volumn 68, Issue 6, 2007, Pages 379-385

  Tomino, Yasu ^a   Yamazaki, T ^a   Shou, I ^a   Tsuge, T ^a   Satake, K ^a   Takeda, Y ^a   Ohtani, A ^a   Nishitani, T ^a   Kurusu, A ^a   Hamada, C ^a   Horikoshi, S ^a   Maeda, K ^b   Tanaka, Y ^b   Fukuda, H ^b   Wakabayashi, M ^c   Seto, T ^c  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

^c JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

Author keywords

Anion exchange resin; Argamate jelly Chronic renal failure patients on conservative treatment; Dose response; RAAS inhibitor

Indexed keywords

ALUMINUM DERIVATIVE; CALCIUM CARBONATE; CANDESARTAN; CREATININE; ENALAPRIL; IMIDAPRIL; INSULIN DERIVATIVE; LOSARTAN; OLMESARTAN; POLYSTYRENESULFONATE CALCIUM; POTASSIUM; SPIRONOLACTONE; TELMISARTAN; VALSARTAN; VITAMIN D DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FORMULATION; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; MALE; MONOTHERAPY; POTASSIUM BLOOD LEVEL;

EID: 37149043155     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp68379     Document Type: Article

References (19)

1. Appel GB, Radhakrishnan J, Avram MV, DeFronzo RA, Escobar-Jimenez F, Campos MM, Burgess E, Hille DA, Dickson TZ, ShahinfarS, BrennerBM. RENAAL Study. Analysis ofmetabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003; 26: 1402-1407.
2. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 2000; 58: 2084-2092.
3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-869.
4. Hatch M, Freel RW, Vaziri ND. Local upregulation of colonic angiotensin II receptors enhances potassium excretion in chronic renal failure. Am J Physiol. 1998; 274: F275-282.
5. Hayashida Y. Research on K transport in the intestines. Jpn J Nephrol. 1978; 20: 619-640.
6. Hene RJ, Boer P, Koomans HA, Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 1982; 21: 98-101.
7. Hirasawa Y. Experience of using KMP-Ca in renal failure patients. Medical Consultation and New Remedies. 1973; 10: 1021-1029.
8. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in Type I-diabetic patients with diabetic nephropathy. J Am Soc Nephrol. 2003; 14: 992-999.
9. Kataoka K. Treatment of hyperkalemia in renal failure with KMP-Ca: experience using calcium polystyrene sulfonatc. Medical Consultation and New Remedies. 1973; 10: 1013-1019.
10. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med. 2001; 345: 851-860.
11. Maeda K, Yamazaki C, Amano T Watanabe Y Ogawa H, Hiramatsu T, Ichida S, Itoh K, Furuhashi M. Clinical study of SK- 189 (Agramate jelly) in hyperkalemia associated with chronic renal failure. Kidney and Dialysis. 2000; 49: 137-152.
12. Maruyama T, Kuno T, Takahashi K, Abe M, Kuragano T, Urae J, Nakuru Y, Matsumoto K, kamimatsuse K. Crossover study of Agramate jelly and powder preparations of anion exchange resin in patients on maintenance dialysis. Clin Dial. 2003; 19: 1643-1649.
13. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aidosterone system. N Engl J Med. 2004; 351 (6): 585-592.
14. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl J Med. 2001; 345: 870-878.
15. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intem Med. 1998; 158: 26-32.
16. Suzuki Y, Mimura N. Inhibitory effects of calcium polystyrene sulfonate (Kalimate) on serum potassium values in hyperkalemia associated with renal failure. Mod Clin. 1973; 15: 794-808.
17. Takashima K, Mizuno K, Arita K, Igarashi S, Seki Y. Comparative testing of Kalimate and Argamate jelly in hemodialysis patients. Jpn J Pharm Health Care Sci. 2004; 30: 584-587.
18. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalburninuria reduction with valsartan in patients with Type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002; 106: 672-678.
19. Wakabayashi M, Shou I, Satake K, Seto T, Maeda K, Tanaka Y, Nakata J, Shimaoka T, Tomino K. Study on the dose response of ajelly preparation of polystyrene sulfonate calciurn in hyperkalemia. Ther Res, 2005; 26: 1727-1733.